Naperville, IL -- (SBWIRE) -- 12/31/2014 -- Reportstack, provider of premium market research reports announces the addition of Cyramza (Colorectal Cancer) - Forecast and Market Analysis to 2023 market report to its offering
Cyramza (Colorectal Cancer) - Forecast and Market Analysis to 2023
Summary
The publisher has released its new PharmaPoint Drug Evaluation report, Cyramza (Colorectal Cancer) - Forecast and Market Analysis to 2023. Colorectal cancer (CRC) is the second leading cause of mortality among cancer patients in the world and is the third most diagnosed cancer globally, and thus represents a huge burden on healthcare systems. This report focuses on the current treatment landscape, unmet needs, current pipeline, and commercial opportunities in the colorectal cancer market, with coverage of multiple settings of the disease including neoadjuvant/adjuvant, first-, second-, third-line KRAS wild-type and mutation-positive, and fourth-line metastatic. In terms of targeted treatments, the metastatic CRC treatment landscape is mature, including the branded treatments Avastin (bevacizumab), Erbitux (cetuximab), and Vectibix (panitumumab), treatments that have extended the survival of metastatic patients compared to chemotherapy-only regimens. However, high unmet needs remain for the extension of survival of metastatic patients, and particularly those with KRAS mutation-positive disease, for whom the epidermal growth factor receptor (EGFR) inhibitors Erbitux and Vectibix are not recommended.
Eli Lillys Cyramza (ramucirumab) is an anti-VEGFR human IgG1 monoclonal antibody angiogenesis inhibitor being investigated by Eli Lilly in Phase III clinical trials for the treatment of metastatic CRC, and has been investigated in a host of other oncology indications, including breast cancer, gastric cancer, HCC, and NSCLC. A Phase III study (RAISE) is investigating ramucirumab as a treatment for second-line metastatic CRC patients who have progressed during, or following, combination treatment with Avastin and FOLFOX. The randomized, double-blind, placebo-controlled study is evaluating ramucirumab in combination with FOLFIRI against FOLFIRI alone in 1,050 metastatic CRC patients.
Scope
- Overview of Colorectal Cancer, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Cyramza including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Cyramza for the top seven countries from 2013 to 2023.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK and Japan.
Reasons to buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Colorectal Cancer
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Cyramza performance
- Obtain sales forecast for Cyramza from 2013-2023 in top seven countries (the US, France, Germany, Italy, Spain, the UK and Japan)
Complete report is available
http://www.reportstack.com/product/188960/cyramza-colorectal-cancer-forecast-and-market-analysis-to-2023.html
Contact:
Roger Campbell
roger@reportstack.com
Naperville
Illinois
United States
Ph: 888-789-6604